Intravitreal drug delivery in retinal disease: Are we out of our depth?

Sachin S. Thakur, Nigel L. Barnett, Mark J. Donaldson, Harendra S. Parekh

Research output: Contribution to journalReview articleResearchpeer-review

25 Citations (Scopus)

Abstract

Introduction: With the ever-increasing global burden of retinal disease, there is an urgent need to vastly improve formulation strategies that enhance posterior eye delivery of therapeutics. Despite intravitreal administration having demonstrated notable superiority over other routes in enhancing retinal drug availability, there still exist various significant physical/biochemical barriers preventing optimal drug delivery into the retina. A further complication lies with an inability to reliably translate laboratory-based retinal models into a clinical setting. Several formulation approaches have recently been evaluated to improve intravitreal therapeutic outcomes, and our aim in this review is to highlight strategies that hold the most promise.Areas covered: We discuss the complex barriers faced by the intravitreal route and examine how formulation strategies including implants, nanoparticulate carriers, viral vectors and sonotherapy have been utilized to attain both sustained delivery and enhanced penetration through to the retina. We conclude by highlighting the advances and limitations of current in vitro, ex vivo and in vivo retinal models in use by researchers globally.Expert opinion: Various nanoparticle compositions have demonstrated the ability to overcome the retinal barriers successfully; however, their utility is limited to the laboratory setting. Optimization of these formulations and the development of more robust experimental retinal models are necessary to translate success in the laboratory into clinically efficacious outcomes.

Original languageEnglish
Pages (from-to)1575-1590
Number of pages16
JournalExpert Opinion on Drug Delivery
Volume11
Issue number10
DOIs
Publication statusPublished - 1 Oct 2014
Externally publishedYes

Fingerprint

Retinal Diseases
Retina
Pharmaceutical Preparations
Architectural Accessibility
Expert Testimony
Nanoparticles
Theoretical Models
Research Personnel
Therapeutics

Cite this

Thakur, Sachin S. ; Barnett, Nigel L. ; Donaldson, Mark J. ; Parekh, Harendra S. / Intravitreal drug delivery in retinal disease : Are we out of our depth?. In: Expert Opinion on Drug Delivery. 2014 ; Vol. 11, No. 10. pp. 1575-1590.
@article{3e3c21ceee6f4e81a80558740d274b5b,
title = "Intravitreal drug delivery in retinal disease: Are we out of our depth?",
abstract = "Introduction: With the ever-increasing global burden of retinal disease, there is an urgent need to vastly improve formulation strategies that enhance posterior eye delivery of therapeutics. Despite intravitreal administration having demonstrated notable superiority over other routes in enhancing retinal drug availability, there still exist various significant physical/biochemical barriers preventing optimal drug delivery into the retina. A further complication lies with an inability to reliably translate laboratory-based retinal models into a clinical setting. Several formulation approaches have recently been evaluated to improve intravitreal therapeutic outcomes, and our aim in this review is to highlight strategies that hold the most promise.Areas covered: We discuss the complex barriers faced by the intravitreal route and examine how formulation strategies including implants, nanoparticulate carriers, viral vectors and sonotherapy have been utilized to attain both sustained delivery and enhanced penetration through to the retina. We conclude by highlighting the advances and limitations of current in vitro, ex vivo and in vivo retinal models in use by researchers globally.Expert opinion: Various nanoparticle compositions have demonstrated the ability to overcome the retinal barriers successfully; however, their utility is limited to the laboratory setting. Optimization of these formulations and the development of more robust experimental retinal models are necessary to translate success in the laboratory into clinically efficacious outcomes.",
author = "Thakur, {Sachin S.} and Barnett, {Nigel L.} and Donaldson, {Mark J.} and Parekh, {Harendra S.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1517/17425247.2014.927864",
language = "English",
volume = "11",
pages = "1575--1590",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare USA",
number = "10",

}

Intravitreal drug delivery in retinal disease : Are we out of our depth? / Thakur, Sachin S.; Barnett, Nigel L.; Donaldson, Mark J.; Parekh, Harendra S.

In: Expert Opinion on Drug Delivery, Vol. 11, No. 10, 01.10.2014, p. 1575-1590.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Intravitreal drug delivery in retinal disease

T2 - Are we out of our depth?

AU - Thakur, Sachin S.

AU - Barnett, Nigel L.

AU - Donaldson, Mark J.

AU - Parekh, Harendra S.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: With the ever-increasing global burden of retinal disease, there is an urgent need to vastly improve formulation strategies that enhance posterior eye delivery of therapeutics. Despite intravitreal administration having demonstrated notable superiority over other routes in enhancing retinal drug availability, there still exist various significant physical/biochemical barriers preventing optimal drug delivery into the retina. A further complication lies with an inability to reliably translate laboratory-based retinal models into a clinical setting. Several formulation approaches have recently been evaluated to improve intravitreal therapeutic outcomes, and our aim in this review is to highlight strategies that hold the most promise.Areas covered: We discuss the complex barriers faced by the intravitreal route and examine how formulation strategies including implants, nanoparticulate carriers, viral vectors and sonotherapy have been utilized to attain both sustained delivery and enhanced penetration through to the retina. We conclude by highlighting the advances and limitations of current in vitro, ex vivo and in vivo retinal models in use by researchers globally.Expert opinion: Various nanoparticle compositions have demonstrated the ability to overcome the retinal barriers successfully; however, their utility is limited to the laboratory setting. Optimization of these formulations and the development of more robust experimental retinal models are necessary to translate success in the laboratory into clinically efficacious outcomes.

AB - Introduction: With the ever-increasing global burden of retinal disease, there is an urgent need to vastly improve formulation strategies that enhance posterior eye delivery of therapeutics. Despite intravitreal administration having demonstrated notable superiority over other routes in enhancing retinal drug availability, there still exist various significant physical/biochemical barriers preventing optimal drug delivery into the retina. A further complication lies with an inability to reliably translate laboratory-based retinal models into a clinical setting. Several formulation approaches have recently been evaluated to improve intravitreal therapeutic outcomes, and our aim in this review is to highlight strategies that hold the most promise.Areas covered: We discuss the complex barriers faced by the intravitreal route and examine how formulation strategies including implants, nanoparticulate carriers, viral vectors and sonotherapy have been utilized to attain both sustained delivery and enhanced penetration through to the retina. We conclude by highlighting the advances and limitations of current in vitro, ex vivo and in vivo retinal models in use by researchers globally.Expert opinion: Various nanoparticle compositions have demonstrated the ability to overcome the retinal barriers successfully; however, their utility is limited to the laboratory setting. Optimization of these formulations and the development of more robust experimental retinal models are necessary to translate success in the laboratory into clinically efficacious outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84907201808&partnerID=8YFLogxK

U2 - 10.1517/17425247.2014.927864

DO - 10.1517/17425247.2014.927864

M3 - Review article

VL - 11

SP - 1575

EP - 1590

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 10

ER -